Biocad

This study is testing a new drug called BCD-261 for adults with moderate to severe ulcerative colitis who haven't gotten enough relief from standard treatments. About 198 participants will receive either the new drug at different doses or a placebo to see which works better at ca…

This study is testing a new drug called BCD-261 for people with moderate to severe Crohn's disease who haven't gotten enough relief from standard treatments. About 204 participants will be randomly assigned to receive one of several doses of the drug or a placebo (an inactive sub…

This study is testing whether a new drug called BCD-281 works as well as an existing reference drug for people with relapsing-remitting multiple sclerosis (RRMS). About 292 participants will be randomly assigned to receive either BCD-281 or the reference drug for 72 weeks, follow…

This study is testing whether a single dose of an experimental gene therapy called ANB-002 can control bleeding as well as, or better than, the standard preventive injections of clotting factor (FIX) in adults with severe hemophilia B. Participants will first be monitored for 6 m…

This early-stage study aims to see how two different concentrations of a new biosimilar drug called BCD-057 compare to the existing drug Humira in healthy men. Researchers will give a single injection to 444 healthy male volunteers and closely track how the drug moves through and…